Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response

British Journal of Cancer

Volumn 101, Issue 3, 2009, Pages 410-417

  Scott, L C ^a   Evans, T R J ^a   Cassidy, J ^a   Harden, S ^b   Paul, J ^b   Ullah, R ^a   O'Brien, V ^c   Brown, R ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Biomarkers; Chemotherapy; Cytokeratin 18; Gastrointestinal adenocarcinomas

Indexed keywords

ASPARTIC ACID; CAPECITABINE; CARBOPLATIN; CASPASE; CISPLATIN; CYTOKERATIN 18; EPIRUBICIN; FLUOROURACIL; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; KERATIN-18; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 68149159205     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605175     Document Type: Article

References (34)

1. Adlbrecht C, Hoetzenecker K, Posch M, Steiner S, Kopp C, Hacker S, Auer J, Horvath R, Moser B, Roth G, Wolner E, Lang IM, Ankersmit HJ (2007) Elevated levels of interleukin-1beta-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction. Eur J Clin Invest 37: 372-380
2. Ausch C, Buxhofer-Ausch V, Olszewski U, Hinterberger W, Ogris E, Schiessel R, Hamilton G (2009) Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur J Surg Oncol (in press)
3. Bantel H, Lugering A, Heidemann J, Volkmann X, Poremba C, Strassburg CP, Manns MP, Schulze-Osthoff K (2004) Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 40: 1078-1087
4. Biven K, Erdal H, Hagg M, Ueno T, Zhou R, Lynch M, Rowley B, Wood J, Zhang C, Toi M, Shoshan MC, Linder S (2003) A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 8: 263-268
5. Bodenmuller H, Donie F, Kaufmann M, Banauch D (1994) The tumor markers TPA, TPS, TPACYK and CYFRA 21-1 react differently with the keratins 8, 18 and 19. Int J Biol Markers 9: 70-74
6. Brockmann JG, St Nottberg H, Glodny B, Sprakel B, Senninger N (2000) Analysis of serum CYFRA 21-1 concentrations in patients with esophageal cancer. Anticancer Res 20: 4899-4904
7. Byrne DJ, Browning MC, Cuschieri A (1990) CA72-4: a new tumour marker for gastric cancer. Br J Surg 77: 1010-1013
8. Caulin C, Salvesen GS, Oshima RG (1997) Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138: 1379-1394
9. Chou CF, Riopel CL, Rott LS, Omary MB (1993) A significant soluble keratin fraction in 'simple' epithelial cells. Lack of an apparent phosphorylation and glycosylation role in keratin solubility. J Cell Sci 105 (Part 2): 433-444
10. Cummings J, Ranson M, Butt F, Moore D, Dive C (2007) Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol 60: 921-924
11. Gaspar MJ, Arribas I, Coca MC, Diez-Alonso M (2001) Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol 22: 318-322
12. Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C (2008) Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 19: 990-995
13. Heptner G, Domschke S, Domschke W (1989) Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnostics of gastrointestinal malignancies. Scand J Gastroenterol 24: 745-750
14. Hostetter RB, Augustus LB, Mankarious R, Chi KF, Fan D, Toth C, Thomas P, Jessup JM (1990) Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst 82: 380-385
15. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P (1999) Measuring response in solid tumors: unidimensional vs bidimensional measurement. J Natl Cancer Inst 91: 523-528
16. Koelink PJ, Lamers CB, Hommes DW, Verspaget HW (2009) Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 9: 88
17. Koprowski H, Herlyn M, Steplewski Z, Sears HF (1981) Specific antigen in serum of patients with colon carcinoma. Science 212: 53-55
18. Kramer G, Schwarz S, Hagg M, Havelka AM, Linder S (2006) Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 94: 1592-1598
19. Kronenberger B, Wagner M, Herrmann E, Mihm U, Piiper A, Sarrazin C, Zeuzem S (2005) Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C. J Viral Hepat 12: 307-314
20. Ku NO, Liao J, Omary MB (1997) Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272: 33197-33203
21. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornvall H, Schutte B (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187: 567-572
22. MacFarlane M, Merrison W, Dinsdale D, Cohen GM (2000) Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis. J Cell Biol 148: 1239-1254
23. Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ (2001) Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol 34: 248-253
24. Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, Barak V (1998) Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 82: 1850-1859
25. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S (2007) Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13: 3198-3206
26. Paterson AJ, Schlom J, Sears HF, Bennett J, Colcher D (1986) A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72.3. Int J Cancer 37: 659-666
27. Roth GA, Krenn C, Brunner M, Moser B, Ploder M, Spittler A, Pelinka L, Sautner T, Wolner E, Boltz-Nitulescu G, Ankersmit HJ (2004) Elevated serum levels of epithelial cell apoptosis-specific cytokeratin 18 neoepitope m30 in critically ill patients. Shock 22: 218-220
28. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Miyazawa Y, Shiratori T, Hayashi H, Gunji Y, Ochiai T (2003) Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma. J Am Coll Surg 196: 573-578
29. Srivastava S, Srivastava RG (2005) Proteomics in the forefront of cancer biomarker discovery. J Proteome Res 4: 1098-1103
30. Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14: 804-810
31. Ucar E, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M (2008) Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. Adv Ther 25: 1075-1084
32. Ueno T, Toi M, Biven K, Bando H, Ogawa T, Linder S (2003) Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 39: 769-774
33. Yang YF, Li H, Xu XQ, Diao YT, Fang XQ, Wang Y, Zhao DL, Wu K, Li HQ (2008) An expression of squamous cell carcinoma antigen 2 in peripheral blood within the different stages of esophageal carcinogenesis. Dis Esophagus 21: 395-401
34. Yen TC, Lin WY, Kao CH, Cheng KY, Wang SJ (1998) A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol Allied Sci 23: 82-86